In 70 years, the Krka Group has grown from a domestic laboratory into one of the top-ranking global generic pharmaceutical companies.

Krka Group’s competitive edge lies in its rich experience, development-oriented mentality, innovative solutions, high-quality generic medicines, continuous investment in advanced technologies, and an extensive production, registration, and marketing-and-sales network.

Krka Group’s strategy positions it as a generic pharmaceutical company. Its reliable supply and output exceeding 18 billion tablets and capsules make it a strong partner to patients and healthcare systems in the treatment of most common diseases.

The Krka Group generates more than €1.9 billion annually with sales of products and services placing it among the leading generic pharmaceutical companies in the world. Innovative generic products, investments and expansion to new markets warrant market share growth and good business performance.

The Krka Group is committed to quality, innovation and development, allocating 10% of revenue to research and development. When it comes to health, only the best is good enough. That is why the Krka Group meticulously plans the development of each medicine. It controls all its production phases, from the development of the active substance to the manufacture of the finished product, to ensure quality throughout its life cycle.